1095009-44-1
Chemical Structure
LXY3
Synonym(s): LXY2
- CAS No.: 1095009-44-1
- Formula:C32H43N11O15S2
- Molecular Weight:885.88
InChIKey: VALZMCWLPCJDLL-OPUINZJVSA-N
SMILES: O=C1[C@]2(N(C[C@H](O)C2)C(CNC([C@H](CC3=CC([N+]([O-])=O)=C(O)C=C3)NC(CNC([C@@H](CC(O)=O)NC([C@H](N)CSSC[C@H](C(N)=O)NC([C@H](CC(N)=O)N1)=O)=O)=O)=O)=O)=O)[H]
Biological Activity: LXY3 (LXY2) is a VLA-3-blocking peptide that inhibits the interaction between integrin α3β1 (VLA-3) on neutrophil surfaces and laminin in the basement membrane, thereby preventing neutrophil migration across the tumor vascular basement membrane barrier. LXY3 is used to block neutrophil-mediated nanoparticle release from perivascular pools into the tumor interstitium. LXY3 is commonly employed for targeted imaging of breast cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
LXY3 | 98.33% | LXY3 (LXY2) is a VLA-3-blocking peptide that inhibits the interaction between integrin α3β1 (VLA-3) on neutrophil surfaces and laminin in the basement membrane, thereby preventing neutrophil migration across the tumor vascular basement membrane barrier. LXY3 is used to block neutrophil-mediated nanoparticle release from perivascular pools into the tumor interstitium. LXY3 is commonly employed for targeted imaging of breast cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Wang Q, et al. Breaking through the basement membrane barrier to improve nanotherapeutic delivery to tumours. Nat Nanotechnol. 2024 Jan;19(1):95-105. [Content Brief]
- [2]. Yao N. Discovery of targeting ligands for breast cancer cells using the one-bead one-compound combinatorial method. J Med Chem. 2009 Jan 8;52(1):126-33. [Content Brief]
